PVI
ELVN icon

Pura Vida Investments’s Enliven Therapeutics ELVN Stock Holding History

Pura Vida Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,159
Closed -$370K – 231
2022
Q1 		$370K Buy
49,159
+275
+0.6% +$1.81K 0.01% 210
2021
Q4 		$440K Buy
+48,884
New +$641K 0.02% 213

Other funds holding ELVN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pura Vida Investments's ELVN Position: Q2 2022 in Review

Pura Vida Investments sold out of Enliven Therapeutics (ELVN) in Q2 2022, closing a stake of 49,159 shares — an estimated $370K sold.

Pura Vida Investments first reported a position in ELVN in Q4 2021 and held it in 2 quarters. The position peaked at $440K in Q4 2021. 26 funds tracked by Wall St. Rank hold ELVN as of Q2 2022.

  • Pura Vida Investments reported no remaining Enliven Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 49,159 Enliven Therapeutics shares in Q2 2022, an estimated $370K.
  • Pura Vida Investments first reported a position in Enliven Therapeutics in Q4 2021 and held it in 2 quarters.
  • Pura Vida Investments's Enliven Therapeutics position peaked at $440K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.